



MiniMed® 640G System^

OUR MOST ADVANCED BREAKTHROUGH IN GLUCOSE CONTROL



« it thinks »

it thinks

ABOUT YOUR PROTECTION
ABOUT YOUR DAY



Our most advanced breakthrough in glucose control.

You think a lot about controlling your glucose levels, but it's challenging because diet, stress and exercise can all affect it. What if you had a system that could give you better control? What if you had a system that could think?

MiniMed® 640G features our exclusive SmartGuard™ technology that thinks¹ about your diabetes and helps you achieve better glucose control.²

MiniMed® 640G System[^]

The unique **MiniMed® connection** offers secure insulin delivery, with an infusion set for every lifestyle.



INSULIN
DELIVERY

Our enhanced **Enlite™ sensor and new Guardian™ 2 Link transmitter** allow continuous monitoring of glucose levels with greater performance and comfort.^{4,5}

CONTINUOUS
GLUCOSE
MONITORING



MiniMed® 640G
with SmartGuard™

BG TESTING
WITH REMOTE
BOLUSING



The exclusive and simple to use blood glucose meter **CONTOUR® NEXT LINK 2.4** from Bayer links wirelessly to the MiniMed® 640G, providing accurate³ testing with Multipulse™ technology, and discreet remote bolusing.

THERAPY
MANAGEMENT
TOOLS



Medtronic CareLink® software includes easy-to-interpret trend reports and useful therapy considerations to support treatment optimisation.




ADVANCED PROTECTION WITH SMARTGUARD™

Our exclusive SmartGuard™ technology is available only with the MiniMed® 640G system.[^] This feature mimics some of the functions of a healthy pancreas by automatically stopping insulin delivery when your sensor glucose is predicted to approach a low limit — and resuming delivery when your levels recover.^{6,7}



Dynamically stopping insulin delivery reduces the length of low glucose levels, as well as the number of nocturnal hypoglycaemic events.^{8,9}

How **SmartGuard™** works in the MiniMed® 640G (for illustration purposes only)



DIABETES IS ALREADY COMPLICATED. YOUR SYSTEM SHOULDN'T BE.

GREATER¹⁰ CONVENIENCE

MiniMed® 640G helps you closely match your insulin needs to your daily routine. You can set friendly reminders or personalised bolus doses and basal patterns. Also, the simple home screen and menu layout minimise steps needed to manage your diabetes, so you can focus more on your day.



MORE INFORMATIVE¹¹ BOLUS WIZARD™ CALCULATOR



PROGRAMMABLE TREATMENT REMINDERS



REMOTE BOLUS FROM METER



SIMPLE-TO-SET PRESET BOLUS AND BASAL PATTERNS



LOUDER¹⁰, VOLUME-ADJUSTABLE ALERTS

IMPROVED DESIGN

The bold, new design of the MiniMed® 640G was inspired by years of feedback from people like you, who want their technology to be smart — and easy to use.



WATERPROOF FOR UP TO 3.6 METRES FOR UP TO 24 HOURS (IPX8)¹²



FULL-COLOUR, AUTO-BRIGHTNESS DISPLAY



INTUITIVE SCREEN NAVIGATION



ERGONOMIC DESIGN FOR RIGHT- AND LEFT-HANDED USERS

MiniMed® 640G is available in five accent colours.



Manage your diabetes with technology that thinks. Ask your doctor today for more information about MiniMed® 640G, the SmartGuard™ system design.



Web: www.medtronic-diabetes.com.au **Email:** australia.diabetes@medtronic.com

Facebook: www.facebook.com/MedtronicDiabetesAUS **Twitter:** @DiabetesANZ **YouTube:** Medtronic Diabetes ANZ

Address: Medtronic Australasia Pty Ltd, 97 Waterloo Road, North Ryde NSW 2113 Australia **Mail:** Medtronic Diabetes, PO Box 945, North Ryde, NSW 1670 **Telephone:** 02 9857 9000 **Facsimile:** 02 9857 9237 **24-hour Toll Free:** 1800 777 808[^]

This information is designed to help you learn more about Diabetes therapy. It is intended to provide you with helpful information but is for information purposes only, is not medical advice and should not be used as an alternative to speaking with your doctor. Be sure to discuss questions specific to your health and treatments with a healthcare professional. For more information please speak to your healthcare professional or log on to: www.medtronic.com.au

References: [^]Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology. ¹Please note: In contacting the Diabetes Toll Free, personal and health information may be disclosed to an operator located outside Australia. **1.** Think refers to the data retrieval, processing and computing capabilities found in the MiniMed® 640G insulin pump, continuous glucose monitoring system (Guardian™ 2 Link transmitter and Enlite™ sensor), Contour® Next LINK 2.4 blood glucose meter and Medtronic CareLink® therapy management software, both collectively and individually. This system and its computing capabilities are part of, but not a replacement for, your daily diabetes management. A confirmatory fingerstick is still required prior to making adjustments to diabetes therapy. **2.** Compared to multiple daily injections, according to the STAR 3 clinical study: Bergenstal RM, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. NEJM. 2010;363:311–320. **3.** Section 8 Clinical Study. Data on File. Bayer Healthcare, LLC. **4.** MiniMed® 640G with Enlite™ has a MARD of 14.2 percent [Enlite Sensor Performance Report] when calibrated 3-4 times daily. **5.** U.S. Enlite Clinical Study Customer Satisfaction Survey. Data on file, Medtronic MiniMed, Inc., Northridge, CA. **6.** The dynamic suspend feature is based on certain criteria: sensor glucose must be at or within 3.9 mmol/L above the low limit and predicted to be no more than 1.1 mmol/L above the low limit within 30 minutes AND the pump must not be in the refractory period. The dynamic resume feature is based on certain preset criteria: sensor glucose must be at least 1.1 mmol/L above the preset low limit and predicted to be greater than 2.2 mmol/L above the low limit within 30 minutes AND insulin must have been suspended for at least 30 minutes. **7.** Must be using Guardian™ 2 Link transmitter with Enlite™ sensor to enable the SmartGuard™ feature on the MiniMed® 640G insulin pump. **8.** Bergenstal RM, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. NEJM. 2013;369(3):224-232. **9.** Agrawal P, et al. Usage and Effectiveness of the Low Glucose Suspend Feature of the MiniMed® Paradigm™ Veo™ Insulin Pump. Diab Sci Tech. 2011;5:1137-1141. **10.** Compared to MiniMed® Paradigm™ Veo™ system. **11.** Calculation is based on the amount of insulin currently in the body, the amount of carbohydrates, the user's current and target blood sugar levels, their insulin-to-carb ratio and their body's sensitivity to insulin. Proper Bolus Wizard™ setup must be completed first. Users must input the number of carbohydrates they are eating and their current blood glucose value before the Bolus Wizard™ can calculate the insulin users should take. **12.** At time of manufacture up to 3.6 metres for up to 24 hours at a time. See *MiniMed® 640G User Guide* for a complete description of the waterproof capabilities and proper use instructions.

Safety Information: MiniMed® 640G Insulin Pump is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. In addition, the Enlite™ glucose sensor is indicated for continuous or periodic monitoring of glucose levels in the fluid under the skin, and possible low and high glucose episodes. The pump displays continuous sensor glucose values and stores this data so that it can be analysed to track patterns and improve diabetes management. This data can be downloaded to a computer for analysis of historical sensor glucose values. The continuous sensor glucose values provided by the MiniMed® 640G insulin pump are not intended to be used directly for making therapy adjustments. Rather, they provide an indication that a confirmation fingerstick measurement may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not based on the value displayed by the pump. Please refer to the *MiniMed® 640G User Guide* for complete details. **Safety Information: Medtronic CareLink®** software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into Medtronic CareLink® reports. The reports provide information that can be used to identify trends and track daily activities, such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: Medtronic CareLink® report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment.

Contour and Bayer are registered trademarks and Multipulse is a trademark of Bayer Healthcare LLC. MiniMed and Medtronic CareLink are registered trademarks and Guardian, Enlite, SmartGuard and Bolus Wizard are trademarks of Medtronic MiniMed, Inc. ©2014 Medtronic Australasia Pty Ltd. All rights reserved. EX16-122014